6 citations,
January 2021 in “Journal of the American Academy of Dermatology” PRP treatments for hair loss need standard protocols to be reliable.
3 citations,
July 2022 in “BMC chemistry” The methods accurately measure finasteride and tadalafil in Entadfi™ capsules for quality control.
Finasteride and testosterone are the drugs most linked to male infertility, but many other potential drugs may be under-reported.
Some drugs may increase the risk of obstructive sleep apnea, while others like certain biologics might decrease it.
May 2016 in “The Journal of Sexual Medicine” Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.
3 citations,
September 2020 in “Molecular Brain” The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
October 2023 in “Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy” New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
January 2023 in “RSC Advances” The study developed accurate, precise, and environmentally friendly methods to measure Finasteride and Tadalafil in a new FDA-approved combination.
1 citations,
April 2018 in “Sleep” Finasteride increases risk of sleep apnea and insomnia.
October 2021 in “European urology open science” August 2018 in “Journal of The American Academy of Dermatology” 110 citations,
August 2016 in “Drugs” Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
30 citations,
January 2000 in “Dermatologic Clinics” Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.
20 citations,
May 2015 in “Regenerative Medicine” The document warns against US clinics selling untested stem cell treatments without FDA approval.
16 citations,
May 2019 in “International Journal of Women's Dermatology” The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.
15 citations,
October 2017 in “Journal of Cosmetic and Laser Therapy” FDA-cleared devices may help treat hair loss, but more research needed; consult dermatologist before use.
9 citations,
November 2021 in “PubMed” FDA-approved low-level light/laser therapy devices can significantly increase hair density in people with pattern hair loss.
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
January 2018 in “Springer eBooks” Lasers are FDA-approved for permanent hair reduction, not removal, and more research is needed to improve treatments.
January 2012 in “Human health handbooks” Low-level light therapy is FDA-approved for male pattern hair loss, increases hair count and strength, and is considered safe for use.
May 2011 in “Value in Health” No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.
1 citations,
October 2022 in “Molecular therapy” The FDA approved the first gene therapy for a blood disorder after overcoming early challenges and demonstrating patient benefits.
1 citations,
May 2006 in “Expert Opinion on Therapeutic Patents” No FDA-approved treatments for chemotherapy-induced hair loss existed in 2006; more research was needed.
March 2021 in “Clin-Alert” The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
71 citations,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” There are no FDA-approved treatments for Alopecia Areata, and current options have varying success and relapse rates.
1 citations,
January 2024 in “Skin research and technology” Deoxycholic acid is FDA-approved for reducing submental fat, but its mechanisms are not fully understood.
1 citations,
February 2022 in “JAMA Dermatology” Minoxidil and finasteride are FDA-approved treatments for male hair loss, but off-label use of oral minoxidil, dutasteride, and higher doses of finasteride and minoxidil is increasing.
April 2022 in “Medicina estética” Minoxidil is the only FDA-approved treatment for female hair loss, with other potential treatments needing more research for effectiveness.
July 2011 in “Springer eBooks” The document concluded that FDA-approved treatments like minoxidil and finasteride are effective for hair loss, while the effectiveness of natural remedies and other non-approved treatments is not well-supported by evidence.